Is physician price sensitivity sufficient to reduce healthcare spend or are stricter payer-led controls required?

October 21, 2019

As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.

Related capabilities